Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD
SAN FRANCISCO–(BUSINESS WIRE)–Expedition Therapeutics, a biotech company developing therapies for novel inflammatory and respiratory diseases, today announced the closing of an oversubscribed and upsized $165 million Series A financing. The round was co-led by Sofinnova…